Ranbaxy, Japanese growth for olmesartan drive Daiichi Sankyo
This article was originally published in Scrip
Executive Summary
Global sales of Daiichi Sankyo's top product, the antihypertensive olmesartan and its combinations, rose by 5% to ¥121.6 billion ($1.51 billion) in the first half ended 30 September.